EP1019049A1 - Molecules apparentees a la retinoide destinees au traitement du diabete sucre non-insulinodependant - Google Patents
Molecules apparentees a la retinoide destinees au traitement du diabete sucre non-insulinodependantInfo
- Publication number
- EP1019049A1 EP1019049A1 EP98911919A EP98911919A EP1019049A1 EP 1019049 A1 EP1019049 A1 EP 1019049A1 EP 98911919 A EP98911919 A EP 98911919A EP 98911919 A EP98911919 A EP 98911919A EP 1019049 A1 EP1019049 A1 EP 1019049A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tetrahydro
- benzoic acid
- tetramethyl
- naphthyloxy
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to the discovery that certain retinoid related compounds which are structurally related to 9-cis retinoic acid effectively induce the differentiation of preadipocytes to adipocytes. These compounds, and compositions containing, are useful for the treatment and/or prevention of non-insulin dependent diabetes mellitus (NIDDM).
- NIDDM non-insulin dependent diabetes mellitus
- NIDDM non- insulin dependent diabetes mellitus
- NIDDM is characterized by insulin resistance and abnormalities relating to insulin secretion and action. More specifically, NIDDM is characterized by hyperglycemia, the result of insulin resistance in peripheral tissue (skeletal muscle and adipose tissue), which occurs because insulin- stimulated uptake/utilization of glucose is blunted therein; and in the liver, which occurs because insulin suppression of glucose output is insufficient. These impairments in insulin action play an important role in the development of elevated fasting blood glucose and glucose intolerance.
- NIDDM treatments and prevention include diet and exercise (since NIDDM and insulin resistance strongly correlates with obesity).
- oral administration of hypoglycemic drugs to control blood glucose levels is another means of treating NIDDM.
- hypoglycemic agents include insulin and sulfonylurea-containing formations.
- these therapies suffer from significant disadvantages, in particular, the occurrence of potentially life-threatening hypoglycemia which is attributable to hyperinsulinemia. This is problematic as hypoglycemia is associated with an elevated risk of cardiovascular disease, the major killer of diabetics. Therefore, providing a method of treating diabetes that does not increase circulatory insulin concentrations would be highly beneficial.
- thiazolidinediones which drugs have been shown to increase sensitivity to insulin in patients that are resistant to this hormone.
- Thiazolidinediones reportedly ameliorate insulin-resistance and normalize plasma glucose and insulin (where elevated) without causing a hypoglycemic state, even when administered at very high dosages.
- the TZD insulin sensitizers e.g., ciglitazone, englitazone, pioglitazone, BRL 49653 (5-[(4-(2- (methyl-2-pyridinylamino)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione) and troglitazone, enhance insulin-mediated suppression of hepatic glucose output and insulin-stimulated glucose uptake and utilization by adipose tissue. Also, TZDs have been reported to alter glucose transporter (e.g. Glut 4) expression which contributes to increased insulin responsiveness.
- glucose transporter e.g. Glut 4
- TZDs One specific TZD member, troglitazone, was recently reported to be effective against NIDDM in a phase III clinical trial (Nolan et al, N. Engl. J. Med., 331 : 1188-1193, 1994).
- the potency of TZDs as effective anti-diabetic agents closely matches that adipogenic action, i.e. their ability to differentiate preadipocytes into adipocytes (Harris and Kletzien, Mol. Pharmacol, 45:439- 445, 1994; Wilson et al, J. Med. Chem., 39:665-668, 1996).
- TZDs have been reported to convert myogenic cells into adipocyte-like cells (Teboul et al, J. Biol. Chem., 270:28183-28187, 1995).
- TZDs have been shown to function as regulators of the nuclear receptor PPAR ⁇ (Lehmann et al, J. Biol. Chem.,
- NIDDM NIDDM
- specific retinoids of the present invention are not mentioned therein.
- the present invention relates to the discovery that specific retinoid- related molecules, which do not exhibit typical retinoid activities, may be used as therapeutics. These compounds, unlike normal retinoids, exhibit reduced or no ability to induce the differentiation of F9 teratocarcinoma cells or P12 pluripotent teratocarcinoma cells. However, these compounds very potently potentially induce the differentiation of preadipocytes to adipocytes.
- Figure 1 compares the ability of various retinoids according to the invention to induce the differentiation of preadipocytes to adipocytes at different concentrations.
- Figure 2 compares the ability of various retinoids according to the invention to induce the differentiation of preadipocytes to adipocytes over a seven day time period.
- compositions adopted for the treatment or prevention of NIDDM that comprise the combination of at least one retinoid-related molecule structurally related to 9-cis retinoic acid, which molecule induces the differentiation of preadipocytes to adipocytes and at least one triazolidinedione (TZD) compound.
- the present invention is based on the discovery that certain retinoid- type molecules, which do not exhibit typical retinoid activities, exhibit the ability to induce differentiation of preadipocytes to adipocytes. Also, these molecules do not exhibit adverse side effects in vivo. This adipogenic action renders these compounds, and isomers or pharmaceutically acceptable salts thereof, well suited for the treatment or prevention of NIDDM. In particular, these compounds should exhibit an effective anti-diabetogenic action based on their adipogenic activity, similar to TZDs. However, unlike TZDs, these retinoid compounds should not exhibit toxic side effects upon in vivo administration because these molecules do not exhibit typical retinoid toxicities and have been shown to be well tolerated in an animals.
- these compounds effectively promote adipogenesis. Therefore, these compounds or isomers or pharmaceutically acceptable salts thereof may be used for the treatment and/or prevention of NIDDM.
- a therapeutic/prophylactic composition which comprises a therapeutically or prophylactically effective amount of at least one compound according to the invention will be administered to a subject having or at risk of developing NIDDM.
- Such pharmaceutical/therapeutic compositions will comprise a vehicle, carrier or diluent which is pharmaceutically acceptable and compatible with the mode of regime of administration selected for the given composition, and a therapeutically or prophylactically effective amount of at least one compound according to the invention, or a pharmaceutically acceptable salt or isomer thereof.
- the administration of the compounds according to the invention can be carried out by any suitable means, e.g., systemically, enterally, parenterally, topically or ocularly. However, oral administration is generally preferred.
- the medicinal/pharmaceutical compositions may be in the form of tablets, gelatin capsules, sugar-coated tablets, syrups, suspensions, elixirs, solutions, powders, granules, emulsions, microspheres or nanospheres or lipid or polymeric vesicles which permit a controlled release.
- the compositions may be in the form of solutions or suspensions for perfusion or for injection.
- the compounds according to the invention are generally administered at a daily dose of about 0.1 mg/kg to 100 mg/kg of body weight which are administered at the rate of 1 to 3 doses per diem.
- the pharmaceutically compositions based on compounds according to the invention may be provided in the form of ointments, creams, milks, pommades, powders, salves, impregnated pads, solutions, gels, sprays, lotions or suspensions. They may also be provided in the form of microspheres or nanospheres or lipid or polymeric vesicles or polymeric patches and hydrogels which permit for controlled release. These compositions for topical administration may, moreover, be provided either in anhydrous form or in an aqueous form. For ocular administration, they are principally eye washes.
- compositions for topical or ocular application contain at least one compound according to the invention or one of its salts, at a concentration preferably ranging from 0.001% to 5% by weight relative to the total weight of the composition.
- compositions according to the invention may, in addition, contain inert or pharmacodynamically active additives.
- the compositions according to the invention may comprise other drugs which are suitable for treating or preventing NIDDM.
- the therapeutic/prophylactic compositions of the invention will comprise at least one retinoid compound according to the invention, in combination with at least one thiazolidinedione compound such as ciglitazone, englitazone, pioglitazone, BRL 49653 (5-[[4-[2-(methyl-2- pyridinylamino)ethoxy]phenyl]methyl]2-4-thiazolidinedione, and troglitazone.
- adipogenic agents should provide at least the additive and potentially synergistic effects on adipogenic activity.
- the subject therapeutic or prophylactic compositions may further comprise other drugs useful for the treatment or prevention of diabetes.
- the retinoid compounds of the present invention as noted, will preferably be used to treat persons already diagnosed with NIDDM, i.e., who exhibit an active disease condition.
- another important application of the present invention comprises the use of the subject retinoid compounds for the prevention of NIDDM in persons who are at substantial risk of developing diabetes, e.g. because of genetic and/or other risk factors.
- risk factors include, by way of example, obesity, and pancreatic transplant.
- these compounds or pharmaceutically acceptable salts thereof may be used or for treating persons who exhibit the early, i.e., preclinical signs of NIDDM.
- Methods for identifying persons who exhibit the early signs of NIDDM or who are at substantial risk of developing NIDDM are known in the diabetic art, and include measuring glucose levels.
- 3T3-L1 preadipocyte cells were seeded at 5xl0 4 cells per well in DMEM and 10% calf serum in 24 well tissue culture plates. Two days after reaching confluence, differentiation was induced by the addition of different compounds according to the invention as well as suitable control compounds in DMEM containing 10% fetal calf serum. Media and compounds were changed every three days. Cells were fixed after 7 days post-confluency and the accumulation of lipid droplets in the cytoplasm was determined by oil red O staining. All cells, including the control cells (vehicle), were treated with the same volume of dimethyl sulfoxide (DMSO), at a level which did not exceed 0.2% final solvent concentration.
- DMSO dimethyl sulfoxide
- Oil red O staining Seven days post confluency, the cells were washed twice with PBS, fixed at 10% formalin and washed one more time with PBS. Cells were then stained with 60% Oil Red O solution for 30 minutes. Cells were then washed twice with water for 15 minutes each.
- the Oil Red O stock solution was prepared from 0.5 g Oil Red O dissolved in 100 ml isopropanol and it was filtered prior dilution in PBS to render 60% Oil Red O solution.
- 3T3-L1 preadipocyte cells were seeded at 5xl0 4 cells per well in DMEM and 10% calf serum in 24 well tissue culture plates. Two days after reaching confluence, differentiation was induced by addition of the different compounds according to the invention in DMEM containing 10% fetal calf serum (Day 0). Media and compounds were changed every three days. Cells were fixed at the indicated days and processed as explained in Example I.
- DMSO dimethyl sulfoxide
- cells were treated with 10 ⁇ g insulin per ml and 1 ⁇ M dexamethasone (Ins/Dex). 1 ⁇ M All-trans RA (tRA) and 2 ⁇ M 9-cis RA (9cRA) were used as additional controls.
- control compounds insulin, dexmethasone, all-trans RA and
- the results obtained substantiate that the compounds of the invention effectively induce adipogenesis in a time and concentration-dependent manner. Accordingly, they should provide effective therapeutic and/or prophylactic agents for treating and/or preventing NIDDM in subjects in need of such treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Physical Vapour Deposition (AREA)
Abstract
La présente invention concerne des procédés permettant de traiter et/ou de prévenir le diabète sucré non-insulinodépendant chez des sujets souffrant de cette maladie ou présentant un risque important de la développer. Lesdits procédés font appel à des composés rétinoïdes spécifiques structurellement apparentés à l'acide rétinoïque 9-cis qui induit la différenciation des préadipocytes en adipocytes. Ces composés peuvent être administrés seuls ou en combinaison avec d'autres agents antidiabetogènes tels que les thiazolidinediones.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3560497P | 1997-03-24 | 1997-03-24 | |
US35604P | 1997-03-24 | ||
PCT/US1998/005591 WO1998042340A1 (fr) | 1997-03-24 | 1998-03-24 | Molecules apparentees a la retinoide destinees au traitement du diabete sucre non-insulinodependant |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1019049A1 true EP1019049A1 (fr) | 2000-07-19 |
Family
ID=21883695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98911919A Withdrawn EP1019049A1 (fr) | 1997-03-24 | 1998-03-24 | Molecules apparentees a la retinoide destinees au traitement du diabete sucre non-insulinodependant |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1019049A1 (fr) |
JP (1) | JP2001521551A (fr) |
KR (1) | KR20010005678A (fr) |
CN (1) | CN1256630A (fr) |
AU (1) | AU6576398A (fr) |
BR (1) | BR9808054A (fr) |
CA (1) | CA2284192A1 (fr) |
IL (1) | IL132032A0 (fr) |
NO (1) | NO994612L (fr) |
NZ (1) | NZ337927A (fr) |
WO (1) | WO1998042340A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR023699A1 (es) * | 1998-11-12 | 2002-09-04 | Smithkline Beecham Corp | Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica |
DE69939485D1 (de) * | 1998-11-12 | 2008-10-16 | Smithkline Beecham Plc | Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin |
WO2002100396A1 (fr) * | 2001-06-07 | 2002-12-19 | Wyeth | Combinaison d'un inhibiteur de la ptpase et d'un agent thiazolidinedione |
CN1921843A (zh) * | 2004-01-23 | 2007-02-28 | 独立行政法人科学技术振兴机构 | 含视黄酸的糖尿病治疗药 |
CN106211757B (zh) * | 2014-01-17 | 2022-06-07 | 康奈尔大学 | 使用维甲酸受体激动剂治疗代谢综合征相关病况的方法 |
US11191755B2 (en) | 2014-01-17 | 2021-12-07 | Cornell University | Compositions and methods for providing cardioprotective effects |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0465508T3 (da) * | 1989-03-08 | 2000-08-07 | Univ Virginia | Diætsupplement til insulinresistente diabetikere |
FR2695317B1 (fr) * | 1992-09-07 | 1995-03-10 | Monal Lab | Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant. |
DE69423806T2 (de) * | 1993-01-22 | 2000-08-17 | Kanegafuchi Chemical Ind | Therapeutisches Agens für NIDDM |
US5478852C1 (en) * | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
US5444086A (en) * | 1994-03-31 | 1995-08-22 | American Home Products Corporation | Naphthalenylmethyl thiophenones as antihyperglycemic agents |
-
1998
- 1998-03-24 JP JP54585198A patent/JP2001521551A/ja active Pending
- 1998-03-24 IL IL13203298A patent/IL132032A0/xx unknown
- 1998-03-24 BR BR9808054-7A patent/BR9808054A/pt not_active Application Discontinuation
- 1998-03-24 KR KR1019997008746A patent/KR20010005678A/ko not_active Application Discontinuation
- 1998-03-24 CA CA002284192A patent/CA2284192A1/fr not_active Abandoned
- 1998-03-24 AU AU65763/98A patent/AU6576398A/en not_active Abandoned
- 1998-03-24 WO PCT/US1998/005591 patent/WO1998042340A1/fr not_active Application Discontinuation
- 1998-03-24 EP EP98911919A patent/EP1019049A1/fr not_active Withdrawn
- 1998-03-24 NZ NZ337927A patent/NZ337927A/xx unknown
- 1998-03-24 CN CN98805131A patent/CN1256630A/zh active Pending
-
1999
- 1999-09-22 NO NO994612A patent/NO994612L/no not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9842340A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2284192A1 (fr) | 1998-10-01 |
KR20010005678A (ko) | 2001-01-15 |
IL132032A0 (en) | 2001-03-19 |
BR9808054A (pt) | 2000-11-07 |
AU6576398A (en) | 1998-10-20 |
NZ337927A (en) | 2000-11-24 |
CN1256630A (zh) | 2000-06-14 |
NO994612L (no) | 1999-11-24 |
NO994612D0 (no) | 1999-09-22 |
JP2001521551A (ja) | 2001-11-06 |
WO1998042340A1 (fr) | 1998-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6028052A (en) | Treating NIDDM with RXR agonists | |
EP0859608B1 (fr) | Traitement de diabetes non insulino-dependants a l'aide d'agonistes de rxr | |
AU678291B2 (en) | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus | |
Spencer et al. | Troglitazone | |
DE60124861T2 (de) | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica | |
US5972944A (en) | Use of thiazolidinedione derivatives in the treatment of anovulation, hyperandrogenism and hirsutism | |
CA2213690A1 (fr) | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf | |
EP1142870A1 (fr) | Nouveaux ligands d'un recepteur nucleaire | |
WO1998042340A1 (fr) | Molecules apparentees a la retinoide destinees au traitement du diabete sucre non-insulinodependant | |
WO1998042340A9 (fr) | Molecules apparentees a la retinoide destinees au traitement du diabete sucre non-insulinodependant | |
EP1294379B1 (fr) | Nouvelle utilisation du deferiprone | |
WO2007007757A1 (fr) | Composition pharmaceutique contenant un agoniste de ppar$g(g) | |
US20040152746A1 (en) | Treatment of scarring and related conditions using ppar-gamma activators | |
EP1637161A1 (fr) | Remede contre des maladies cerebrales neurodegeneratives utilisant un agoniste des ppar$g(d) | |
WO2005079792A1 (fr) | Agents préventifs ou thérapeutiques pour la rétinopathie diabétique sévère | |
MXPA99008765A (en) | Methods and compositions for treating and/or preventing non-insulin dependent diabetes mellitus (niddm) using specific retinoid compounds | |
Sorbera et al. | Netoglitazone | |
US6046202A (en) | Use of thiazolidinedione derivatives in the treatment of insulin resistance | |
JP2005514399A (ja) | PPARγアクチベーターの投薬法 | |
JP3007683B2 (ja) | 新規な医薬用途 | |
Wang | Focus on repaglinide: an oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas | |
RU2191007C2 (ru) | Способ лечения иhcд агонистами rxr | |
Shinkai | Recent developments in oral hypoglycemic agents | |
CA2232288C (fr) | Traitement de diabetes non insulino-dependants a l'aide d'agonistes de rxr | |
MXPA98002104A (en) | Compositions using a rxr agonist only or in combination with a ppar agonist, to treat diabetes mellitus not dependent on insul |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19991001 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 20010118 |